Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan

Shigeki Nakamura, Masashi Mikami, Tomoyuki Hayamizu, Naohiro Yonemoto, Camille Moyon, Mark Gouldson, Catriona Crossan, Jeffrey Vietri, Kazumasa Kamei*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal conjugate vaccines (PCVs) for adults aged 65 years and high-risk adults aged 60–64 years in Japan. Research design and methods: Using a Markov model, we evaluated lifetime costs using societal and healthcare payer perspectives and estimated quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by invasive pneumococcal disease (IPD) and non-IPD. The base case analysis used a societal perspective. Results: In comparison with PPSV23, the 20-valent PCV (PCV20) prevented 127 IPD cases 10,813 non-IPD cases (inpatients: 2,461, outpatients: 8,352) and 226 deaths, and gained more QALYs (+0.0015 per person) with less cost (-JPY22,513 per person). All sensitivity and scenario analyses including a payer perspective analysis indicated that the incremental cost-effectiveness ratios (ICERs) were below the cost-effectiveness threshold value in Japan (JPY5 million/QALY). Conclusions: PCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60–64 years in Japan.

Original languageEnglish
Pages (from-to)546-560
Number of pages15
JournalExpert Review of Vaccines
Volume23
Issue number1
DOIs
StatePublished - 2024

Keywords

  • Cost-effectiveness
  • Japan
  • PCV20
  • invasive pneumococcal disease
  • pneumococcal disease
  • vaccination

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan'. Together they form a unique fingerprint.

Cite this